Prognostic model for the red blood cell-platelet ratio and its trajectory categories during ICU stay. by Jie Zhao (49409)

CONSORT flow diagram depicting participant flow through the trial. by Leigh V. Evans (19753987)

Human parasitology infection intensity data. by Roland Proud (11764892)

Human parasitology prevalence data. by Roland Proud (11764892)

Prognostic Impact of Red Blood Cell-Platelet Ratio Trajectory Categories after PSM. by Jie Zhao (49409)

Summary of snail survey effort and count data. Occupancy and counts are given as area averages across site means, with associated site mean ranges given in brackets. Note that both... by Roland Proud (11764892)

Metabolic analysis of cecal contents. by Ye Cheng (513097)

Rut inhibited the degradation of TJPs to reduce BBB breakdown and also suppressed apoptosis of brain tissue cells. by Zhixuan Huang (6750410)

The red blood cell-platelet ratio affects prognosis. by Jie Zhao (49409)

Red blood cell-platelet ratio and HR-restriction cube diagram during hospitalization. by Jie Zhao (49409)

Impact of red blood cell-platelet ratio trajectories in the first four days before ICU admission on prognosis and clinical outcomes in the validation set. by Jie Zhao (49409)

Rut alleviated BBB damage in MCAO rats and exerted neuroprotective effects. by Zhixuan Huang (6750410)

Effect of Rut on neuronal injury caused by OGD. by Zhixuan Huang (6750410)

Impact of red blood cell-platelet ratio trajectories on prognosis and clinical outcomes in the first four days before ICU admission in the training set. by Jie Zhao (49409)

Glucagon-like peptide-1 receptor agonists, inflammation, and kidney diseases: evidence from Mendelian randomization by Yu-Xuan Yao (21338594)

“…</p> <p>After meta-analyses of both discovery and validation cohorts, genetically proxied GLP1R agonist was found to significantly associated with a decreased risk of diabetic nephropathy (OR = 0.72, 95%CI = 0.54–0.97, <i>p</i> = 0.031) and IgA nephropathy (OR = 0.58, 95%CI = 0.36–0.94, <i>p</i> = 0.027). …”

DataSheet1_Apolipoprotein A-I attenuates peritoneal fibrosis associated with peritoneal dialysis by inhibiting oxidative stress and inflammation.ZIP by Jing Lu (120666)

“…Yet little is known about apoA-I ’s role in peritoneal dialysis. In this study, by analyzing PD patients (n = 81), we found that decreased apoA/HDL-C ratio is significantly associated with rapid decline in peritoneal function. …”

High-intensity light induces rod and cone cell death in <i>clrn1</i>^-/- zebrafish. by Hannah J. T. Nonarath (20861735)

“…Quantification of (h) WGA- and (i) PNA-positive outer segments along a 100 µm section of the central retina revealed a significant decrease in rod and cone outer segments in light-damaged <i>clrn1</i>^<i>-/-</i> zebrafish. …”

(A) Mobility rate, (B) Explored areas, (5C) Immobility time, (D) Frozen events for hole board test. by Hammad Ismail (4227988)

Fragmentation patterns for Schisandrin A. by Zhaoping Meng (4875040)

“…Twenty-two differential metabolites (VIP ≥ 1) were identified using untargeted metabolomics. 3 primary metabolites, namely mannose, pyruvate, and shikimic acid, together with 2 secondary metabolites, phenylalanine and mevalonic acid, were observed to decrease. 17 secondary metabolites, including Schisandrin A, Schisandrin B, Schisandrin C, Gomisin D, Gomisin G, Gomisin H, Benzoylgomisin H, Benzoylgomisin O,Angeloylgomisin P, Catechin, Isorhamnetin, Luteolin, Cinnamic acid, Hydroxycinnamic acid, Hexahydrocurcumin, Coniferyl alcohol, Phenylalanine, Terpinolene and Mevalonic acid, exhibited increases in their levels by 10.64, 1.84, 1.40, 1.64, 4.46, 8.18, 1.72, 10.20, 2.08, 1.27, 1.57, 1.18, 2.01, 1.12, 1.88, 1.15, and 3.17-fold, respectively. …”

Chemical structure of a lignan. by Zhaoping Meng (4875040)

“…Twenty-two differential metabolites (VIP ≥ 1) were identified using untargeted metabolomics. 3 primary metabolites, namely mannose, pyruvate, and shikimic acid, together with 2 secondary metabolites, phenylalanine and mevalonic acid, were observed to decrease. 17 secondary metabolites, including Schisandrin A, Schisandrin B, Schisandrin C, Gomisin D, Gomisin G, Gomisin H, Benzoylgomisin H, Benzoylgomisin O,Angeloylgomisin P, Catechin, Isorhamnetin, Luteolin, Cinnamic acid, Hydroxycinnamic acid, Hexahydrocurcumin, Coniferyl alcohol, Phenylalanine, Terpinolene and Mevalonic acid, exhibited increases in their levels by 10.64, 1.84, 1.40, 1.64, 4.46, 8.18, 1.72, 10.20, 2.08, 1.27, 1.57, 1.18, 2.01, 1.12, 1.88, 1.15, and 3.17-fold, respectively. …”